Andrew Beelen

Apr 19, 2024 | accp1.onlinelibrary.wiley.com | Richard Preston |Emily Dumas |Thomas C. Marbury |Andrew Beelen

Introduction Trilaciclib is a novel drug that acts as an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in regulating the cell cycle.1, 2 Specifically, CDK4/6 are responsible for facilitating the transition from the G1 phase to the S phase, during which DNA replication takes place. By impeding the activity of CDK4/6, trilaciclib can induce a temporary and reversible halt in the cell cycle at the G1 phase.